Dr Molly Reynolds

B. Clin. Sci/M.D

Neuroimmunology, particularly peripheral disorders such as Myasthenia Gravis and CIDP and central nervous system disorders such as MS, nerve conduction studies, general neurology including stroke, epilepsy and headache.

Dr Molly Reynolds is a consultant neurologist with clinical expertise in neuroimmunology, with a particular focus on peripheral nervous system conditions such as myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP). She completed her neurology advanced training in New South Wales before undertaking a neuroimmunology and neuromuscular fellowship at Concord Repatriation General Hospital in Sydney.

Her fellowship training provided extensive experience in the diagnosis and management of complex peripheral neuroimmunological conditions, including myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP) and related neuromuscular disorders. A key focus of her training was the combined neuroimmunology clinic model, which shaped her commitment to holistic, multidisciplinary care. She is passionate about ensuring patients with chronic neurological disease and long-term immunosuppression receive comprehensive management that addresses their broader healthcare needs.

As part of her training, Dr Reynolds achieved neurophysiology credentialing with the Australian and New Zealand Association of Neurologists (ANZAN), providing expertise in performing both routine and complex nerve conduction studies and electromyography. This enables clinical assessment and diagnostic investigations to occur concurrently, supporting timely diagnosis of complex conditions.

Dr Reynolds maintains an active research interest in neuroimmunological disease with a particular focus on improving early and accurate diagnosis of Guillain-Barré syndrome and optimising patient outcomes with immunosuppressive therapies. She is currently involved in multiple clinical trials investigating novel treatments for myasthenia gravis, CIDP, multifocal motor neuropathy (MMN) and multiple sclerosis, reflecting her commitment to advancing clinical evidence and providing patients with access to emerging therapies.

• Mater Private Hospital Gold Coast